|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Held
for Sale Assets and Liabilities
On March 20, 2006, we completed the sale of the European
rights to Prialt to Eisai, which is included in our
Biopharmaceuticals segment, while retaining the product rights
in the United States. In accordance with SFAS 144, we
reclassified the related assets (intangible assets, inventory,
and prepayments) as held for sale to present them separately on
the Consolidated Balance Sheet.
Share capital at December 31, 2005 and 2004 was as follows:
The Executive Shares do not confer on the holders thereof the
right to receive notice of, attend or vote at any of our
meetings, or the right to be paid a dividend out of our profits,
except for such dividends as the directors may from time to time
determine.
The “B” Executive Shares confer on the holders thereof
the same voting rights as the holders of Ordinary Shares. The
“B” Executive Shares do not confer on the holders
thereof the right to be paid a dividend out of our profits
except for such dividends as the directors may from time to time
determine.
Table of Contents
Elan
Corporation, plc
NOTES TO
THE CONSOLIDATED FINANCIAL
STATEMENTS — (Continued)
At the Annual General Meeting in May 1999, we were authorized to
repurchase up to 15% of the issued share capital on that date.
During the remainder of the year ended December 31, 1999,
we purchased 621,500 Ordinary Shares of Elan at a cost of
$17.4 million and these are currently held in treasury
stock. In 2000, we terminated our share repurchase program.
The components of accumulated other comprehensive income/(loss),
net of $Nil taxes, were as follows (in millions):
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
